| 产品描述: | 寡聚聚集抑制剂;抑制病毒蛋白和α-突触核蛋白聚集体形成;Oligomeric aggregation inhibitor; inhibits prion protein and α-synuclein aggregate formation;; |
| 体内研究: |
Emrusolmin 显示出与病理聚集体的结构依赖性结合,并在体外和体内强烈抑制朊病毒蛋白和 α-突触核蛋白病理寡聚体的形成。 Emrusolmin (0.6-2 g/kg;口服) 调节 α-突触核蛋白寡聚化。 |
| 参考文献: |
1. Wagner J, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125(6):795-813. 2. Martinez Hernandez A, et al. The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med. 2018;10(1):32-47. 3. Heras-Garvin A, et al. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019;34(2):255-263. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.914 ml |
14.57 ml |
29.139 ml |
| 5 mM |
0.583 ml |
2.914 ml |
5.828 ml |
| 10 mM |
0.291 ml |
1.457 ml |
2.914 ml |
| 50 mM |
0.058 ml |
0.291 ml |
0.583 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |